Related Experiment Video
Updated: Jun 21, 2025
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
Published on: April 29, 2015
Programming of in Situ Tumor Vaccines via Supramolecular Nanodrug/Hydrogel Composite and Deformable Nanoadjuvant for
Shuaiqi Shao1, Ziyang Cao2, Zekai Xiao1
1School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong 511442, People's Republic of China.
Abstract:
The development of in situ tumor vaccines offers promising prospects for cancer treatment. Nonetheless, the generation of plenary autologous antigens in vivo and their codelivery to DC cells along with adjuvants remains a significant challenge. Herein, we developed an in situ tumor vaccine using a supramolecular nanoparticle/hydrogel composite (ANPMTO/ALCD) and a deformable nanoadjuvant (PPER848). The ANPMTO/ALCD composite consisted of β-cyclodextrin-decorated alginate (Alg-g-CD) and MTO-encapsulated adamantane-decorated nanoparticles (ANPMTO) through supramolecular interaction, facilitating the long-term and sustained production of plenary autologous antigens, particularly under a 660 nm laser. Simultaneously, the produced autologous antigens were effectively captured by nanoadjuvant PPER848 and subsequently transported to lymph nodes and DC cells, benefiting from its optimized size and deformability. This in situ tumor vaccine can trigger a robust antitumor immune response and demonstrate significant therapeutic efficacy in inhibiting tumor growth, suppressing tumor metastasis, and preventing postoperative recurrence, offering a straightforward approach to programming in situ tumor vaccines.
Insights
This study presents a novel in situ tumor vaccine using a nanoparticle/hydrogel composite and a deformable nanoadjuvant. This approach effectively generates tumor antigens and enhances immune response for cancer treatment.
Area of Science:
- Biotechnology
- Immunology
- Materials Science
Background:
- In situ tumor vaccines show promise for cancer treatment.
- Challenges include in vivo antigen generation and codelivery with adjuvants.
Purpose of the Study:
- To develop an advanced in situ tumor vaccine using a supramolecular nanoparticle/hydrogel composite (ANPMTO/ALCD) and a deformable nanoadjuvant (PPER848).
- To achieve sustained autologous antigen production and effective delivery to immune cells.
Main Methods:
- Fabrication of a supramolecular composite (ANPMTO/ALCD) from alginate and MTO-loaded nanoparticles.
- Utilized a deformable nanoadjuvant (PPER848) for antigen capture and transport.
- Employed a 660 nm laser to stimulate antigen production.
Main Results:
- The ANPMTO/ALCD composite enabled long-term, sustained production of autologous antigens.
- The PPER848 nanoadjuvant efficiently captured antigens and transported them to lymph nodes and dendritic cells (DC cells).
- The vaccine triggered a robust antitumor immune response, inhibiting tumor growth and metastasis.
Conclusions:
- The developed in situ tumor vaccine demonstrates significant therapeutic efficacy.
- It effectively suppresses tumor growth, metastasis, and postoperative recurrence.
- This offers a simplified strategy for programming effective in situ tumor vaccines.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...